AR100209A1 - Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos - Google Patents

Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos

Info

Publication number
AR100209A1
AR100209A1 ARP150101268A ARP150101268A AR100209A1 AR 100209 A1 AR100209 A1 AR 100209A1 AR P150101268 A ARP150101268 A AR P150101268A AR P150101268 A ARP150101268 A AR P150101268A AR 100209 A1 AR100209 A1 AR 100209A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
halogen
treatment
substituted
glyt1
Prior art date
Application number
ARP150101268A
Other languages
English (en)
Inventor
Pinard Emmanuel
Winter Michael
Alberati Daniela
Koerner Annette
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR100209A1 publication Critical patent/AR100209A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Son inhibidores de GlyT1, para su uso en el tratamiento de trastornos hematológicos, en particular, para su uso en el tratamiento de enfermedad de células falciformes y talasemia, o para el tratamiento de pacientes con síndromes de sobrecarga de hierro, tales como la hemocromatosis hereditaria. Reivindicación 5: Un inhibidor de GlyT1 de acuerdo con una cualquiera de las reivindicaciones 1 - 4, en el que el inhibidor de GlyT1 se selecciona de un compuesto de fórmula (1) en los que R¹ es halógeno, alquilo inferior sustituido con halógeno, ciano o S(O)₂-alquilo inferior; R² es alquilo inferior, alquilo inferior sustituido con halógeno o es (CH₂)ₒ-cicloalquilo; R³ es alquilo inferior, NH₂ o amino sustituido con uno o dos alquilos inferiores; X C o N; n es 1 ó 2; o es 0, 1 ó 2; así como sales de adición de ácido farmacéuticamente aceptables del mismo; o es un compuesto de fórmula (2) en el que R¹ es halógeno, alquilo inferior, alquilo inferior sustituido con halógeno, alcoxi, ciano o S(O)₂-alquilo inferior; R² es alquilo inferior, alquilo inferior sustituido con halógeno o es (CH₂)ₒ-cicloalquilo; R³ es alquilo inferior, NH₂ o amino sustituido con uno o dos alquilos inferiores; X es C o N; X¹ es C o N; en el que solo uno de X y X¹ es N; n es 1 ó 2; o es 0, 1 ó 2; así como sales de adición de ácido farmacéuticamente aceptables del mismo.
ARP150101268A 2014-04-30 2015-04-28 Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos AR100209A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14166497 2014-04-30

Publications (1)

Publication Number Publication Date
AR100209A1 true AR100209A1 (es) 2016-09-21

Family

ID=50677958

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101268A AR100209A1 (es) 2014-04-30 2015-04-28 Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos

Country Status (18)

Country Link
US (1) US9877963B2 (es)
EP (1) EP3137073B1 (es)
JP (1) JP6283766B2 (es)
KR (1) KR101869185B1 (es)
CN (1) CN106163520B (es)
AR (1) AR100209A1 (es)
CY (1) CY1120508T1 (es)
ES (1) ES2683184T3 (es)
HR (1) HRP20181205T1 (es)
MA (1) MA39927B1 (es)
MY (1) MY189930A (es)
PH (1) PH12016501784A1 (es)
PT (1) PT3137073T (es)
RS (1) RS57535B1 (es)
SG (2) SG11201608397UA (es)
SI (1) SI3137073T1 (es)
TR (1) TR201809598T4 (es)
WO (1) WO2015165842A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3199156A1 (de) * 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
CU20200106A7 (es) * 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
CN115279372A (zh) * 2020-01-09 2022-11-01 迪斯克医药公司 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
WO2022192731A1 (en) * 2021-03-12 2022-09-15 Disc Medicine, Inc. Compositions and methods for treating anemia associated with a ribosomal disorder
JP2024518091A (ja) * 2021-05-14 2024-04-24 ディスク・メディシン・インコーポレイテッド グリシン輸送阻害剤を用いて赤血球増殖性プロトポルフィリン症、x連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法
JP2024520391A (ja) * 2021-05-27 2024-05-24 ディスク・メディシン・インコーポレイテッド ビトペルチンの固体形態を用いて赤血球増殖性プロトポルフィリン症、x連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法
WO2023235326A1 (en) * 2022-05-31 2023-12-07 Disc Medicine, Inc. Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00116B (me) * 2003-08-11 2010-10-10 Hoffmann La Roche Piperazin sa ili supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
RS51204B (sr) * 2005-02-07 2010-12-31 F. Hoffmann-La Roche Ag. Heterociklični supstituisani fenil metanoni kao inhibitori glicin transportera 1

Also Published As

Publication number Publication date
KR101869185B1 (ko) 2018-06-19
CN106163520A (zh) 2016-11-23
US20170042888A1 (en) 2017-02-16
MA39927B1 (fr) 2018-09-28
MA39927A (fr) 2017-03-08
SG11201608397UA (en) 2016-11-29
MY189930A (en) 2022-03-22
EP3137073A1 (en) 2017-03-08
EP3137073B1 (en) 2018-06-06
ES2683184T3 (es) 2018-09-25
KR20160130517A (ko) 2016-11-11
CN106163520B (zh) 2019-12-13
CY1120508T1 (el) 2019-07-10
PH12016501784B1 (en) 2016-11-07
RS57535B1 (sr) 2018-10-31
JP6283766B2 (ja) 2018-02-21
SI3137073T1 (sl) 2018-09-28
WO2015165842A1 (en) 2015-11-05
TR201809598T4 (tr) 2018-07-23
SG10201909382UA (en) 2019-11-28
PT3137073T (pt) 2018-07-27
JP2017511385A (ja) 2017-04-20
HRP20181205T1 (hr) 2018-09-21
US9877963B2 (en) 2018-01-30
PH12016501784A1 (en) 2016-11-07

Similar Documents

Publication Publication Date Title
AR100209A1 (es) Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201790202A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
CR20150045A (es) Inhibidores de hepatitis c
EA201690989A1 (ru) Ингибиторы syk
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
ECSP13013074A (es) Nuevos derivados de piridina
CR20150447A (es) Nuevos derivados de pirazol
EA201492281A1 (ru) Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
DOP2014000016A (es) Indazoles novedosos inhibidores de janus quinasa
CO7350652A2 (es) Piridina-2-amidas útiles como agonistas de cb2
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201592182A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
NI201200192A (es) Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica.
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
CR20150204A (es) Nuevos derivados de piridina
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы

Legal Events

Date Code Title Description
FC Refusal